acute radiation syndrome


Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

acute radiation syndrome

[ə′kyüt ′rād·ē′a·shən ′sin‚drōm]
(medicine)
A complex of symptoms involving the intestinal tract, blood-forming organs, and skin following whole-body irradiation.
References in periodicals archive ?
Maxygen submitted a white paper entitled Development of MAXY-G34 as a Medical Countermeasure for Acute Radiation Syndrome in December 2010 in response to a Broad Agency Announcement (BAA-10-100-SOL-00012).
Because no products are licensed to treat any aspect of acute radiation syndrome, BARDA is supporting the development of products to treat bone marrow, gastrointestinal, lung, and skin injury caused by radiation.
WASHINGTON -- The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.
This includes the gastrointestinal acute radiation syndrome program which is funded by both the National Institute of Allergy and Infectious Diseases (NIAID; up to $6.
We are delighted to welcome Oreola to our team, as she will leverage her extensive preclinical and early stage clinical drug development expertise in leading our SGX94, gastrointestinal acute radiation syndrome (GI ARS) and melioidosis programs.
The contract is for the advanced preclinical development of OrbeShield(TM) (oral beclomethasone 17,21-dipropionate or oral BDP) as a MCM for the treatment of gastrointestinal acute radiation syndrome (GI ARS).
The contract is for the advanced preclinical and manufacturing development of OrbeShield(TM) (oral beclomethasone 17,21-dipropionate or oral BDP) as a MCM for the treatment of gastrointestinal acute radiation syndrome (GI ARS).
OTC: AOLS), a biopharmaceutical company developing a new class of broad spectrum catalytic antioxidant compounds that reduce oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure, today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS), has awarded Aeolus a contract for the advanced development of AEOL 10150 as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (ARS).
OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient SGX94 for the treatment of acute radiation syndrome (ARS).
Full browser ?